Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering).

Last updated: October 24, 2016
Sponsor: Gerald Maguire, MD
Overall Status: Trial Status Unknown

Phase

2/3

Condition

Autism

Speech Disorders

Communication Disorders

Treatment

N/A

Clinical Study ID

NCT02909088
EcoUCR001
IND 128278
  • Ages 18-60
  • All Genders

Study Summary

The primary objective of this study is to evaluate the efficacy and tolerability of ecopipam in reducing stuttering symptoms.

It is hypothesized that ecopipam effectively reduces stuttering symptoms as measured on the SSI-IV total score, the CGI, SSS and OASES.

Eligibility Criteria

Inclusion

Inclusion Criteria: Subjects can be enrolled in the study only if they meet all of the following criteria:

  1. Subjects must satisfy DSM-IV criteria for childhood onset fluency disorder (stuttering).

  2. The nature of stuttering must be developmental in origin with the onset prior to tenyears of age.

  3. Subjects must have a score of moderate or higher on the SSI-IV.

  4. Women of child-bearing potential are eligible to participate as long as they arepracticing a medically accepted form of contraception (i.e. condom with spermicide ordiaphragm, oral or depot contraception, or an intrauterine device).

  5. Subjects will be male or female from the ages of 18-60.

  6. Subject must have a MADRS total score of ≤ 13 (normal mood)

  7. Subjects will be of only English speaking.

Exclusion

Exclusion Criteria: Subjects will be excluded from the study for any of the following reasons:

  1. Adult individuals who lack capacity to consent for themselves.

  2. Stuttering related to a known neurologic cause (e.g. head trauma, stroke).

  3. Unstable medical or psychiatric illness.

  4. Active substance abuse within three months prior to study inclusion.

  5. Any illness that would require the concomitant use of a CNS active medication duringthe course of the study.

  6. Subjects with Parkinson's dementia or other degenerative neurologic illness.

  7. Suffer from irregular heart rate or seizures

  8. Subjects who are pregnant or nursing an infant.

  9. Subject with a MADRS ≥ 14

  10. Breastfeeding a child during the course of the study or for one month followingcompletion

  11. It is the investigator's opinion that the subject poses a significant suicide risk bythe following criteria:

  12. It is the investigator's opinion that the subject may be at risk of suicide.

  13. the subject responds "yes" to question #4 (Active Suicidal Ideation with SpecificPlan and Intent) on the Baseline Visit of the Columbia Suicide Severity RatingScale (C-SSRS), if the most recent episode occurred within the past 12 months.

Study Design

Total Participants: 10
Study Start date:
September 01, 2016
Estimated Completion Date:
November 30, 2017

Connect with a study center

  • CITrials

    Riverside, California 92506
    United States

    Active - Recruiting

  • University of California Riverside School of Medicine

    Riverside, California 92521
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.